Healthcare workers in poor nations often do not have enough protective gear to keep them safe from being infected with blood-borne viruses such as Ebola and HIV, according to a study published online Aug. 8 in Tropical Medicine & International Health.
By Gale Scott
Results of a large international study known as SIGNIFY showed ivabradine offered no benefit to patients who had stable coronary artery disease without clinical heart failure (CHF).
By Gale Scott
Novartis plans to soon file a new drug application with the US Food and Drug Administration (FDA) for its investigational heart failure drug LCZ696. A report showing the drug works better than enalapril to prevent adverse cardiac events was released at the European Society of Cardiology Congress in Barcelona, Spain Aug. 30 and published online in the New England Journal of Medicine (NEJM).
By Jeannette Wick
Adolescent transgender patients face many challenges, as do the medical professionals who care for them. What is the best way to manage transgender youths? This is a complex question with answers that rely on a case-by-case, ethical approach
By Amy Jacob
Researchers at the University of Leicester have developed a highly sensitive “electronic-nose” to identify the infectious bacteria Clostridium difficile that causes diarrhea, stomach cramps, and fever in patients.
By Amy Jacob
Monitoring patients’ own intestinal immune responses, researchers at Yale University have identified some of the bacterial culprits driving inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis.
By Andrew Smith
New research suggests that oral immunotherapy may trigger anaphylaxis in an unusually high percentage of asthmatic teenagers with high-risk food allergies who failed to adhere to their management plan.
For patients with stable coronary artery disease without clinical heart failure, ivabradine does not improve outcomes, according to a study published online Aug. 31 in the New England Journal of Medicine. The study was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 30 to Sept. 3 in Barcelona, Spain.
For patients after an acute coronary syndrome event, darapladib inhibition of lipoprotein-associated phospholipase A2 does not reduce the risk of major coronary events, according to a study published online Aug. 31 in the Journal of the American Medical Association. The study was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 30 to Sept. 3 in Barcelona, Spain.
Nine percent of top-selling packaged food products in the United States contain partially hydrogenated oils, with most of these products reporting 0 grams of trans fat per serving, according to a study published Aug. 28 in the U.S. Centers for Disease Control and Prevention's Preventing Chronic Disease.